Get started
Author

Adam Phillip Siegel

At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials
2018 · Hala T. Borno, Li Zhang, et al. · The Oncologist · 124
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer
2018 · Xiao X. Wei, Adam P. Siegel, et al. · The Oncologist · 36
PDF
A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy
2018 · Celia P. Kaplan, Adam Siegel, et al. · Contemporary Clinical Trials Communications · 12
PDF
The problem of representativeness of clinical trial participants: understanding the role of hidden costs
2016 · Hala Borno, Adam Siegel, et al. · Journal of Health Services Research & Policy · 11
Results of a multicenter phase I/II trial of abiraterone acetate plus BEZ235 in metastatic, castration-resistant prostate cancer (mCRPC).
2014 · Adam Phillip Siegel, Alan Haruo Bryce, et al. · Journal of Clinical Oncology · 6
Machine Learning Assessment of Background Parenchymal Enhancement in Breast Cancer and Clinical Applications: A Literature Review
2024 · Katie S. Duong, Rhianna Rubner, et al. · Cancers · 4
PDF
Results of a phase II trial of selinexor, an oral selective inhibitor of nuclear export (SINE), in patients with metastatic castration resistant prostate cancer (mCRPC) refractory to abiraterone or enzalutamide.
2017 · Xiao Wei, Adam Phillip Siegel, et al. · Journal of Clinical Oncology
Approaches Targeting Androgen Synthesis (CYP 17 Inhibitors)
2014 · Adam Siegel, Charles J. Ryan · Current clinical urology
Works count: 8
Citation count: 193
H-index: 5
I10-index: 4
Year
Topic
Type